Oral Covid Treatment Brings Promising Trial Data: Pharmaceutical Companies

German pharmaceutical company Merck is trying to develop two oral medications to fight Covid-19

German pharmaceutical giant Merck and its US partner reported promising results on Saturday in a trial of a drug given orally to fight COVID-19, saying it would help reduce viral load in patients.

“These preliminary data are encouraging when antiviral treatment needs for SARS-CoV-2 are not met,” said Wendy Painter, Ridgeback Biotherapy, Chief Medical Officer, US company. I will.

In January, Merck stopped researching two COVID vaccine candidates, but proceeded with research on two products to treat the disease, including a pill-based product called molnupiravir developed by Ridgeback Biotherapy. ..

Merck said in a meeting with an infectious disease expert that the drug significantly reduced the patient’s viral load after five days of treatment.

This Phase 2a test, which has three stages of clinical trials before the product is approved, was conducted in 202 unhospitalized individuals with COVID-19 symptoms.

There were no safety warnings and of the four serious adverse events reported, Ridgeback said it was not considered to be related to taking the drug.

Oral antiviral drugs such as oseltamivir (Tamiflu) and zanamivir (Relenza) may be prescribed for seasonal flu, but researchers have not yet come up with a similar one to fight the coronavirus.

William Fisher, a senior researcher and professor of medicine at the University of North Carolina, said the results of this study, a rapid decrease in viral load in early-stage COVID-19 patients treated with molnupiravir, are promising. .. ..

“If supported by additional research, (they) can have significant public health implications, especially as the SARS-CoV-2 virus continues to spread and evolve globally,” Fisher said. He added.

Merck is also working on another oral COVID treatment called MK-711.

In January, the company presented preliminary results from a clinical trial showing that patients hospitalized with moderate to severe COVID-19 had a 50% or greater reduction in risk of death or respiratory distress.

Merck Ends Development of Two Potential COVID-19 Vaccines

© 2021 AFP

Quote: Oral Covid treatment provides promising study data: Pharmaceutical company (March 7, 2021) from Obtained March 7, 2021

This document is subject to copyright. No part may be reproduced without written permission, except for fair transactions for personal investigation or research purposes. The content is provided for informational purposes only.

Oral Covid Treatment Brings Promising Trial Data: Pharmaceutical Companies

Source link Oral Covid Treatment Brings Promising Trial Data: Pharmaceutical Companies

Related Articles

Back to top button